Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma

Melanoma Research

Volumn 22, Issue 4, 2012, Pages 302-309

  McClain, Susannah E ^a   Shada, Amber L ^b   Barry, Megan ^b   Patterson, James W ^b   Slingluff, Craig L ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

lymph node metastasis; regression; sentinel lymph node biopsy; thin melanoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DATA BASE; EXCISION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY;

HUMANS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84863727782     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328353e673     Document Type: Article

References (55)

1. Anstey AV, Arlett CF, Cole J, Norris PG, Hamblin AS, Limb GA, et al. Longterm survival and preservation of natural killer cell activity in a xeroderma pigmentosum patient with spontaneous regression and multiple deposits of malignant melanoma. Br J Dermatol 1991; 125:272-278.
2. Baldo M, Schiavon M, Cicogna PA, Boccato P, Mazzoleni F. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast Reconstr Surg 1992; 90:1073-1076.
3. Cole WH, Everson TC. Spontaneous regression of cancer: preliminary report. Ann Surg 1956; 144:366-383.
4. Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Ronan SG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002; 138:603-608.
5. McGovern VJ. Spontaneous regression of melanoma. Pathology 1975; 7:91-99.
6. Wagner SN, Schultewolter T, Wagner C, Briedigkeit L, Becker JC, Kwasnicka HM, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78:541-550.
7. Wang TS, Lowe L, Smith JWN, Francis IR, Sondak VK, Dworzanian L, et al. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 1998; 24:915-919.
8. High WA, Stewart D, Wilbers CR, Cockerell CJ, Hoang MP, Fitzpatrick JE. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol 2005; 53:89-100.
9. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 2001; 93:1047-1048.
10. Breslow A, Macht SD. Evaluation of prognosis in stage I cutaneous melanoma. Plast Reconstr Surg 1978; 61:342-346.
11. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978; 42:2282-2292.
12. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg 1983; 118:41-44.
13. Slingluff CLJ, Vollmer RT, Reintgen DS, Seigler HF. Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208:150-161.
14. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol 1985; 408:241-247.
15. Clark WHJ, Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-1904.
16. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17:389-395.
17. Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol 1985; 121:1127-1131.
18. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer 1985; 56:2287-2291.
19. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983; 7:673-680.
20. Trau H, Rigel DS, Harris MN, Kopf AW, Friedman RJ, Gumport SL, et al. Metastases of thin melanomas. Cancer 1983; 51:553-556.
21. Wanebo HJ, Cooper PH, Hagar RW. Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg 1985; 201:499-504.
22. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008; 15:316-322.
23. Cecchi R, Pavesi M, Buralli L, Innocenti S, De Gaudio C. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital 2008; 60:257-260.
24. Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, Lauwers F, Lopez R, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol 2010; 162:830-834.
25. Abramova L, Slingluff CLJ, Patterson JW. Problems in the interpretation of apparent 'radial growth phase' malignant melanomas that metastasize. J Cutan Pathol 2002; 29:407-414.
26. Smith JLJ, Stehlin JSJ. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 1965; 18:1399-1415.
27. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123:1326-1330.
28. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
29. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
30. Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 2006; 13:533-541.
31. Sondak VK, Taylor JM, Sabel MS,Wang Y, Lowe L, Grover AC, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11:247-258.
32. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22:3668-3676.
33. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97:1488-1498.
34. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12:449-458.
35. Thompson JF, Shaw HM. Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy? Ann Surg Oncol 2004; 11:233-235.
36. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 2005; 42:460-534.
37. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21:1326-1331.
38. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
39. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-535, discussion 535-537.
40. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg 2003; 50:601-606.
41. Puleo CA, Messina JL, Riker AI, Glass LF, Nelson C, Cruse CW, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005; 12:230-235.
42. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol 2004; 11:900-906.
43. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13:302-309.
44. Olah J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003; 149:662-663.
45. Kramkimel N, Maubec E, Boitier F, Cavalcanti A, Beldi M, Mamelle G, et al. Tumour regression is not predictive for higher risk of sentinel node involvement in thin melanomas (Breslow thickness
46. Kaur C, Thomas RJ, Desai N, Green MA, Lovell D, Powell BW, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol 2008; 61:297-300.
47. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
48. Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (
49. Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillen C. Problems in defining melanoma regression and prognostic implication. Actas Dermosifiliogr 2009; 100:759-766.
50. Ceballos PI, Barnhill RL. Spontaneous regression of cutaneous tumors. Adv Dermatol 1993; 8:229-261, discussion 262.
51. Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat Histopathol 1992; 420:113-115.
52. Barr RJ. The many faces of completely regressed malignant melanoma. Pathology 1994; 2:359-370.
53. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991; 97:197-202.
54. Shaw HM, McCarthy SW, McCarthy WH, Thompson JF, Milton GW. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 1989; 15:257-265.
55. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) 2006; 54:323-333.